McKesson: Sustained Rally Backed By Strong Financials

  • The stock price of McKesson has maintained a strong upward trend throughout multiple years because of its solid financial performance and dedicated investor support which creates a defensive investment opportunity. The company achieves strong revenue and EPS growth through its expanding oncology, biopharmaceutical and GLP-1 therapy sales, which counterbalance the typical thin margins of the sector. The company's strategic focus on high-growth segments together with its divestment of slow-growth units makes McKesson an attractive long-term investment despite its high valuation and low yield.